CYV — Ceryvyn Therapeutics Income Statement
0.000.00%
Last trade - 00:00- AU$15.05m
- -AU$14.97m
- AU$0.00m
Annual income statement for Ceryvyn Therapeutics, fiscal year end - June 30th, AUD millions except per share, conversion factor applied.
2022 June 30th | 2023 June 30th | 2024 June 30th | R2025 June 30th | 2026 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | fx Final | fx Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.125 | 0.161 | 0.19 | 0.228 | 0.001 |
| Cost of Revenue | |||||
| Gross Profit | -0.096 | -0.087 | — | — | — |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Operating Interest Expense / Income | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 133 | 224 | 293 | 262 | -330 |
| Operating Profit | -133 | -223 | -293 | -262 | 330 |
| Total Net Non Operating Interest Income / Expense | |||||
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -137 | -221 | -350 | -262 | 330 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -128 | -212 | -336 | -251 | 330 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -128 | -212 | -336 | -251 | 330 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -128 | -212 | -336 | -251 | 330 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.316 | -0.416 | -0.527 | -0.205 | 0.245 |